Olympus Corporation (OLYMY)
OTCMKTS · Delayed Price · Currency is USD
12.82
+0.08 (0.63%)
At close: Feb 11, 2026

Revenue by Geography

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Japan Revenue
106.84B110.11B117.30B
Japan Revenue Growth
-2.98%-6.13%-4.26%
North America Revenue
397.59B413.81B351.25B
North America Revenue Growth
-3.92%17.81%9.03%
Europe Revenue
258.15B254.62B236.77B
Europe Revenue Growth
1.39%7.54%6.57%
China Revenue
85.49B95.72B106.34B
China Revenue Growth
-10.69%-9.98%-9.19%
Asia and Oceania Revenue (Post-FY2019 Reporting)
97.62B93.69B87.99B
Asia and Oceania Revenue (Post-FY2019 Reporting) Growth
4.19%6.48%13.08%
Asia and Oceania Revenue (Pre-FY2020 Reporting)
183.11B189.41B194.32B
Asia and Oceania Revenue (Pre-FY2020 Reporting) Growth
-3.33%-2.53%-0.30%
Other Countries Revenue
31.62B28.84B26.11B
Other Countries Revenue Growth
9.64%10.46%29.42%

Revenue Breakdown

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Endoscopic Solutions Division Revenue
636.14B586.62B
Endoscopic Solutions Division Revenue Growth
8.44%6.30%
Therapeutic Solutions Division Revenue
360.66B337.33B
Therapeutic Solutions Division Revenue Growth
6.92%6.01%
Total Medical Solutions Division Revenue
996.80B923.95B
Total Medical Solutions Division Revenue Growth
7.89%6.20%
Other Division Revenue (Post-FY2024 Reporting)
530.00M1.80B
Other Division Revenue (Post-FY2024 Reporting) Growth
-70.62%-

Revenue Breakdown 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Gastrointestinal Solutions Division Revenue
658.66B674.04B-
Gastrointestinal Solutions Division Revenue Growth
-2.28%--
Surgical & Interventional Solutions Division Revenue
318.64B322.76B-
Surgical & Interventional Solutions Division Revenue Growth
-1.28%--

EBIT

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Endoscopic Solutions Division Operating Profit
141.40B104.68B
Endoscopic Solutions Division Operating Profit Growth
35.07%-31.48%
Therapeutic Solutions Division Operating Profit
61.45B-8.47B
Total Medical Solutions Division Operating Profit
202.85B96.22B
Total Medical Solutions Division Operating Profit Growth
110.82%-55.55%
Other Division Operating Profit (Post-FY2024 Reporting)
-473.00M-287.00M
Eliminations from Division Operating Profit
-39.92B-44.54B

EBIT 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Gastrointestinal Solutions Division Operating Profit
143.72B167.89B-
Gastrointestinal Solutions Division Operating Profit Growth
-14.39%--
Surgical & Interventional Solutions Division Operating Profit
8.24B14.69B-
Surgical & Interventional Solutions Division Operating Profit Growth
-43.89%--

Key Performance Indicators

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment
3.00%-3.00%
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment
5.00%-3.00%
ESD - Medical Service Revenue Growth Rate After FX Adjustment
5.00%8.00%
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment
4.00%1.00%
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment
2.00%6.00%
TSD - Urology Revenue Growth Rate After FX Adjustment
6.00%-1.00%
TSD - Respiratory Revenue Growth Rate After FX Adjustment
10.00%-3.00%
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment
-7.00%-5.00%
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment
3.00%-
Updated Sep 30, 2025. Data Source: Fiscal.ai.